Infant Mortality Clinical Trial
— CS-BCGOfficial title:
Can BCG Vaccination at First Health-facility Contact Reduce Early Infant Mortality? A Cluster Randomised Trial
Bacillus Calmette-Guérin (BCG) vaccination is recommended at birth to protect against tuberculosis (TB) in countries with high TB burden. BCG is supplied in multidose vials with limited durability after reconstitution. In Guinea-Bissau, this has led to a practice of only opening a BCG vial at specific days, and only if sufficient children are present. Therefore, BCG vaccination is frequently delayed. Accumulating evidence indicates that BCG has beneficial effects on survival beyond the specific protection against tuberculosis, so called non-specific effects (NSEs). The hypothesis of this study is that increasing the availability of BCG and vaccinating children at the first health-facility contact can reduce early infant non-accidental mortality by 25%. In a cluster-randomised crossover trial, 23 health facilities (HFs) in three rural regions in Guinea-Bissau will be randomised to either continue with current practice (typically BCG vaccination once a week if a sufficient number of children are present for vaccination); or to offer additional BCG vaccines to make BCG available every day and open a vial of BCG if there is just one eligible child present. All children born in the three regions and registered during the study period, will be eligible for inclusion into the trial 1 day after birth. If consent is given by the mother, the child will be followed until day 42 after birth, when other vaccines are scheduled to be given. The primary outcome will be non-accidental mortality, secondary outcomes are non-accidental hospital admissions, non-accidental neonatal mortality and cost-effectiveness of making BCG available at the first health-facility contact.
Status | Recruiting |
Enrollment | 22800 |
Est. completion date | October 2025 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 1 Day to 42 Days |
Eligibility | Inclusion Criteria: - All children registered during pregnancy in Oio, Biombo or Farim by CHWs or the BHP HDSS Exclusion Criteria: - Children, who have died within 1 day after birth - Children born outside Oio, Biombo and Farim health regions |
Country | Name | City | State |
---|---|---|---|
Guinea-Bissau | Bandim Health Project | Bissau |
Lead Sponsor | Collaborator |
---|---|
Bandim Health Project | University of Southern Denmark |
Guinea-Bissau,
Biering-Sorensen S, Aaby P, Lund N, Monteiro I, Jensen KJ, Eriksen HB, Schaltz-Buchholzer F, Jorgensen ASP, Rodrigues A, Fisker AB, Benn CS. Early BCG-Denmark and Neonatal Mortality Among Infants Weighing <2500 g: A Randomized Controlled Trial. Clin Infect Dis. 2017 Oct 1;65(7):1183-1190. doi: 10.1093/cid/cix525. — View Citation
Curtis N. BCG Vaccination and All-Cause Neonatal Mortality. Pediatr Infect Dis J. 2019 Feb;38(2):195-197. doi: 10.1097/INF.0000000000002230. No abstract available. — View Citation
Higgins JP, Soares-Weiser K, Lopez-Lopez JA, Kakourou A, Chaplin K, Christensen H, Martin NK, Sterne JA, Reingold AL. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016 Oct 13;355:i5170. doi: 10.1136/bmj.i5170. Erratum In: BMJ. 2017 Mar 8;356:j1241. — View Citation
Jayaraman K, Adhisivam B, Nallasivan S, Krishnan RG, Kamalarathnam C, Bharathi M, McSharry B, Namachivayam SP, Shann F, Boopalan SI, David P, Bhat BV. Two Randomized Trials of the Effect of the Russian Strain of Bacillus Calmette-Guerin Alone or With Oral Polio Vaccine on Neonatal Mortality in Infants Weighing <2000 g in India. Pediatr Infect Dis J. 2019 Feb;38(2):198-202. doi: 10.1097/INF.0000000000002198. — View Citation
Kagone M, Ye M, Nebie E, Sie A, Schoeps A, Becher H, Muller O, Fisker AB. Vaccination coverage and factors associated with adherence to the vaccination schedule in young children of a rural area in Burkina Faso. Glob Health Action. 2017;10(1):1399749. doi: 10.1080/16549716.2017.1399749. — View Citation
Lawn JE, Blencowe H, Oza S, You D, Lee AC, Waiswa P, Lalli M, Bhutta Z, Barros AJ, Christian P, Mathers C, Cousens SN; Lancet Every Newborn Study Group. Every Newborn: progress, priorities, and potential beyond survival. Lancet. 2014 Jul 12;384(9938):189-205. doi: 10.1016/S0140-6736(14)60496-7. Epub 2014 May 19. Erratum In: Lancet. 2014 Jul 12;384(9938):132. — View Citation
Mutua, M.K., et al. Analysis of Fully Immunized Child (FIC), Associated Factors, Outcomes, and Impact Using Routinely Population Cohort Data 2001-2014. Report by the INDEPTH Network as a collaboration with GAVI 2015 18th April 2020 ]; Available from: http://www.indepth-network.org/sites/default/files/content/project_pages/files/Fully%20Immunized%20Child%20Report%20and%20Appendices.pdf.
Roth A, Jensen H, Garly ML, Djana Q, Martins CL, Sodemann M, Rodrigues A, Aaby P. Low birth weight infants and Calmette-Guerin bacillus vaccination at birth: community study from Guinea-Bissau. Pediatr Infect Dis J. 2004 Jun;23(6):544-50. doi: 10.1097/01.inf.0000129693.81082.a0. — View Citation
Schaltz-Buchholzer F, Biering-Sorensen S, Lund N, Monteiro I, Umbasse P, Fisker AB, Andersen A, Rodrigues A, Aaby P, Benn CS. Early BCG Vaccination, Hospitalizations, and Hospital Deaths: Analysis of a Secondary Outcome in 3 Randomized Trials from Guinea-Bissau. J Infect Dis. 2019 Jan 29;219(4):624-632. doi: 10.1093/infdis/jiy544. — View Citation
Thysen SM, Benn CS, Gomes VF, Rudolf F, Wejse C, Roth A, Kallestrup P, Aaby P, Fisker A. Neonatal BCG vaccination and child survival in TB-exposed and TB-unexposed children: a prospective cohort study. BMJ Open. 2020 Feb 28;10(2):e035595. doi: 10.1136/bmjopen-2019-035595. — View Citation
Thysen SM, Byberg S, Pedersen M, Rodrigues A, Ravn H, Martins C, Benn CS, Aaby P, Fisker AB. BCG coverage and barriers to BCG vaccination in Guinea-Bissau: an observational study. BMC Public Health. 2014 Oct 4;14:1037. doi: 10.1186/1471-2458-14-1037. — View Citation
Wallace AS, Willis F, Nwaze E, Dieng B, Sipilanyambe N, Daniels D, Abanida E, Gasasira A, Mahmud M, Ryman TK. Vaccine wastage in Nigeria: An assessment of wastage rates and related vaccinator knowledge, attitudes and practices. Vaccine. 2017 Dec 4;35(48 Pt B):6751-6758. doi: 10.1016/j.vaccine.2017.09.082. Epub 2017 Oct 21. — View Citation
World Health Organization. BCG vaccine: WHO position paper, February 2018 - Recommendations. Vaccine. 2018 Jun 7;36(24):3408-3410. doi: 10.1016/j.vaccine.2018.03.009. Epub 2018 Mar 30. — View Citation
* Note: There are 13 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Odds ratio of non-accidental early infant mortality | The primary analysis of early infant non-accidental mortality will be assessed in an intention-to-treat (TT) analysis. Logistic regression models with generalised estimating equation (GEE) correction for village cluster will be used.
Furthermore, an assessment of whether the effect of the intervention on the primary outcome is modified by the following potential effect modifiers, will be carried out: Sex, maternal BCG scar (yes/no), season of birth (dry/rainy), strain of BCG. |
From 1 day after birth to 42 days after birth | |
Secondary | Odds ratio of non-accidental neonatal mortality | Assessment of the effect of BCG availability on the village cluster level non-accidental neonatal mortality based on CHW registration. | From 1 day after birth to 28 days after birth | |
Secondary | Odds ratio of severe morbidity | Non-accidental hospital admissions (defined as overnight hospitalisations or arrival at the hospital and death within the first day) defined by the following potential effect modifiers: sex, maternal BCG scar (yes/no), season of birth (dry/rainy), strain of BCG. | From 1 day after birth to 42 days after birth | |
Secondary | Incremental cost-effectiveness ratio per death averted by making BCG available at the first health facility contact | A cost-effectiveness analysis estimating the incremental costs per death averted by making BCG available at the first health facility contact will be undertaken. Incremental costs will be assessed by contrasting the costs of BCG vaccine provision in the present programme and in a scenario with BCG available at the first health-facility contact as tested in the trial. The costs/savings associated with different rates of consultations and admissions will also be taken into account. This analysis will only be carried out, if the analysis of the primary outcome shows that increasing availability of BCG reduces early infant mortality. | From 1 day after birth to 42 days after birth |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04100577 -
Today Not Tomorrow Pregnancy and Infant Support Program (TNT- PISP)
|
N/A | |
Completed |
NCT03400878 -
Comparing Morbidity and Mortality Effects of Two Different Strains of BCG
|
Phase 4 | |
Terminated |
NCT02504203 -
Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial
|
Phase 4 | |
Active, not recruiting |
NCT00168610 -
Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine
|
Phase 4 | |
Recruiting |
NCT02331082 -
Integrating Pediatric Care Delivery in Rural Healthcare Systems
|
N/A | |
Completed |
NCT02185625 -
Reduction of Adverse Pregnancy Outcomes With a Smartphone Application in Ghana
|
N/A | |
Completed |
NCT00860470 -
Antenatal Micronutrient Supplementation and Infant Survival
|
Phase 3 | |
Completed |
NCT02189265 -
Assessing the Impact of Smoke-free Legislation on Perinatal Health in the Netherlands
|
N/A | |
Completed |
NCT00115271 -
Antenatal Micronutrient Supplementation and Birth Weight
|
Phase 3 | |
Completed |
NCT02039583 -
Impact of Smoke-free Legislation on Early-life Mortality and Low Birth Weight in England
|
N/A | |
Completed |
NCT00198822 -
Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
|
Phase 3 |